Veracyte Acquires Convergent Genomics for $150M to Expand Urology Diagnostics Portfolio

Veracyte (VCYT) announced it has completed the acquisition of Convergent Genomics, a diagnostics company focused on bladder cancer. The acquisition expands Veracyte's urology product portfolio by adding Convergent's UroAmp platform and its proprietary urinary tumor DNA (utDNA) technology, complementing its existing tissue and blood-based tests.

Key Details

• Financial Terms: The deal includes an upfront payment of $150 million in cash, with up to an additional $30 million in cash payable upon the achievement of specific milestones related to UroAmp publications and reimbursement.
• Strategic Rationale: The acquisition adds a urine-based testing platform for non-muscle invasive bladder cancer (NMIBC), aiming to provide comprehensive genomic insights across the patient journey.
• Timeline: The merger agreement was signed on September 10, 2026, and the acquisition was completed on September 14, 2026.